# Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

> **NCT02451488** · PHASE4 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 8 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** GM-CSF
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT02451488
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-11-04
- **Final completion:** 2016-11-04
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02451488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02451488, "Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02451488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*